Go Pro
→ Feds Say Your Cash Isn’t Property—Can They Take It? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.01
+4.4%		$0.00
$0.00
▼
$26,604.72
$6K1.2199.55 million shs6.09 million shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.622,374 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,630 shs12 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
0.00%-6.85%+183.33%-47.29%-100.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%0.00%+400.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.01
+4.4%		$0.00
$0.00
▼
$26,604.72
$6K1.2199.55 million shs6.09 million shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.622,374 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,630 shs12 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
0.00%-6.85%+183.33%-47.29%-100.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%0.00%+400.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aditxt, Inc. stock logo
ADTX
Aditxt
1.00
SellN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EVLO, ADTX, GNCA, and PXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Aditxt, Inc. stock logo
ADTX
Aditxt
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aditxt, Inc. stock logo
ADTX
Aditxt
$14.34K0.40N/AN/A$259.70 per share0.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/A$0.46 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aditxt, Inc. stock logo
ADTX
Aditxt
-$41.71M-$100,788.35N/AN/AN/A-360,152.50%-374.60%-105.93%12/2/2026 (Estimated)
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53M-$4.21N/AN/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%12/2/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.06
0.05
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
4.90%

Insider Ownership

CompanyInsider Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
0.01%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aditxt, Inc. stock logo
ADTX
Aditxt
60816,000816,000No Data
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.84 million18.79 millionNo Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
PaxMedica, Inc. stock logo
PXMD
PaxMedica
211.31 million11.20 millionNot Optionable

Recent News About These Companies

PaxMedica, Inc. (PXMD) - Yahoo Finance
July 11, 2025  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/PXMD/
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
January 14, 2025  |  accesswire.comA
Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
September 23, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/study-links-iron-deficiency-to-disturbed-sleep-among-autism-adhd-patients/ar-AA1r3Lgv
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
September 3, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/biomednewsbreaks-paxmedica-inc-pxmd-announces-immediate-exercise-of-warrants-to-total-approximately-884k/ar-AA1pVZlL
PaxMedica Secures Immediate Exercise of Warrants
September 3, 2024  |  accesswire.comA
Yale Study Unravels Autism, Brain Growth Patterns
September 1, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/yale-study-unravels-autism-brain-growth-patterns/ar-AA1pIVO0
PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/63099646-paxmedica-inc-paxmedica-reports-first-patient-treated-with-pax-101-for-fatal-african-sleeping-sickness-infection-200.htm
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  accesswire.comA
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/15/2882426/0/en/paxmedica-files-nasdaq-delisting-appeal-notice-and-prepares-for-upcoming-fda-meeting-on-pax-101.html
PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024
May 13, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/pxmd-stock-earnings-paxmedica-for-q1-of-2024/?cc=marketbeat&cp=pdtk
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 7, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/paxmedica-provides-company-update-and-continues-to-advance-pax-101-regulatory-strategy-1033339022
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/paxmedica-provides-company-continues-advance-123000325.html?.tsrc=rss
PaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA
May 3, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD/pressreleases/25912106/paxmedica-nasdaq-pxmd-announces-pax-101-batch-completion-for-nda-application-to-fda/
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
April 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/paxmedicas-ceo-malawi-health-official-123000894.html?.tsrc=rss
Urgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawi
April 25, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD-Q/pressreleases/25736118/urgent-action-paxmedica-nasdaq-pxmd-addresses-medical-crisis-in-malawi/
PaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA
April 25, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD-Q/pressreleases/25705963/paxmedica-nasdaq-pxmd-completes-key-step-in-preparation-of-pax-101-for-nda-submission-to-fda/
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
April 23, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/23/2867666/0/en/paxmedica-responds-to-emergency-request-for-iv-suramin-and-commits-to-provide-immediate-access-to-pax-101.html
PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 18, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61968676-paxmedica-inc-paxmedica-receives-emergency-request-for-iv-suramin-from-african-health-ministry-for-use-in-treating-fatal-sleeping-sickness-399.htm
Choosing Unknown Penny Stocks, 3 Top Tips
April 15, 2024  |  pennystocks.comP
PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 12, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61930130-paxmedica-inc-paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on-potential-nda-submission-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aditxt stock logo

Aditxt NASDAQ:ADTX

$0.0071 +0.00 (+4.41%)
As of 01:26 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

PaxMedica stock logo

PaxMedica NASDAQ:PXMD

$0.0005 0.00 (0.00%)
As of 09/11/2026

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas